EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Genetic, Clinical, and Sociodemographic Profile of Individuals with Diagnosis or Family History of Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort

Emerson de Santana Santos iD, Gabriel da Costa Kuhn iD, Antônio Guilherme Cunha de Almeida iD, João Victor Andrade Pimentel iD, Newton Vital Figueiredo Neto iD, Larissa Rebeca da Silva Tavares iD, Bárbara Letícia Lima Dos Santos iD, Ana Beatriz Leite Aragão iD, Beatriz Carolina de Araujo Pereira iD, Caio da Silva Ferreira iD, Willian Moreira Leão E Silva iD, Cardiogenetics Research Group Of Sergipe und 4 weitere

Genes · 2025

DOI: 10.3390/genes16091100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, 2025. Verfasst von Emerson de Santana Santos und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alnylam Pharmaceuticals (United States), Sanofi (Brazil), Alnylam and Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder characterized by left ventricular hypertrophy in the absence of secondary causes. This study aimed to investigate the genetic, clinical, and epidemiological profile of individuals with clinical HCM or a family history of sudden cardiac death (SCD).

Methods

A total of 200 participants (58% male, median age 52 years) underwent genetic testing using a 19-gene panel associated with HCM and phenocopies. Variants were classified as pathogenic/likely pathogenic (P/LP), variants of uncertain significance (VUS), or negative. Clinical and imaging data were correlated with genetic findings.

Results

P/LP variants were identified in 31% of individuals, while 40.5% carried VUS, and 28.5% tested negative. A positive genotype was more frequent among patients with clinical HCM (37.7%) than among those with only a family history (18.6%, p = 0.006). Sarcomeric mutations represented 77.4% of positive results, while 22.6% involved phenocopy genes, notably TTR (amyloidosis). Positive genotypes were significantly associated with a family history of SCD (68% vs. 46%, p = 0.004) and with greater interventricular septal thickness (17 mm vs. 15 mm, p < 0.001).

Conclusions

Septal thickness >17 mm and family history of SCD were strong predictors of positive genetic results. These findings emphasize the importance of genetic screening and counseling in high-risk individuals and highlight the value of integrating genetic testing into clinical practice for diagnosis, risk stratification, and family management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cardiomyopathy, HypertrophicHumansMaleFemaleMiddle AgedAdultProspective StudiesGenetic TestingAgedMutationDeath, Sudden, CardiacGenetic Predisposition to DiseaseGenotype

Stichwörter der Autor:innen

cardiac amyloidosisfamily historygenetic testinghypertrophic cardiomyopathyphenocopies

Autor:innen und Institutionen

  • Department of Medicine, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.
  • Postgraduate Program in Health Sciences, Federal University of Sergipe (UFS), Aracaju 49060-676, Brazil.
  • University Hospital, Federal University of Sergipe, Aracaju 49100-000, Brazil.
  • University Hospital of Lagarto, Federal University of Sergipe, Aracaju 49100-000, Brazil.
  • Department of Medicine, Tiradentes University, Aracaju 49032-490, Brazil.
  • Department of Fisheries and Aquaculture Engineering, Federal University of Sergipe (UFS), Aracaju 49100-000, Brazil.

ORCID-Profile: Emerson de Santana Santos, Gabriel da Costa Kuhn, Antônio Guilherme Cunha de Almeida, João Victor Andrade Pimentel, Newton Vital Figueiredo Neto, Larissa Rebeca da Silva Tavares, Bárbara Letícia Lima Dos Santos, Ana Beatriz Leite Aragão, Beatriz Carolina de Araujo Pereira, Caio da Silva Ferreira, Willian Moreira Leão E Silva, Enaldo Vieira de Melo, Irlaneide da Silva Tavares, Antônio Carlos Sobral Sousa, Joselina Luzia Menezes Oliveira

Förderung

  • Alnylam Pharmaceuticals (United States)
  • Sanofi (Brazil)
  • Alnylam and Sanofi

Zitieren

APA

Santos, E. S., Kuhn, G. D. C., de Almeida, A. G. C., Pimentel, J. V. A., Figueiredo Neto, N. V., Tavares, L. R. D. S., Dos Santos, B. L. L., Aragão, A. B. L., Pereira, B. C. A., Ferreira, C. D. S., Silva, W. M. L. E., Cardiogenetics Research Group Of Sergipe, Melo, E. V., Tavares, I. D. S., Sousa, A. C. S., & Oliveira, J. L. M. (2025). Genetic, Clinical, and Sociodemographic Profile of Individuals with Diagnosis or Family History of Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort. Genes. https://doi.org/10.3390/genes16091100

Vancouver

Santos ES, Kuhn GDC, de Almeida AGC, Pimentel JVA, Figueiredo Neto NV, Tavares LRDS, et al. Genetic, Clinical, and Sociodemographic Profile of Individuals with Diagnosis or Family History of Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort. Genes. 2025. doi:10.3390/genes16091100

BibTeX
@article{Santos2025,
  author = {Santos, Emerson de Santana and Kuhn, Gabriel da Costa and de Almeida, Antônio Guilherme Cunha and Pimentel, João Victor Andrade and Figueiredo Neto, Newton Vital and Tavares, Larissa Rebeca da Silva and Dos Santos, Bárbara Letícia Lima and Aragão, Ana Beatriz Leite and Pereira, Beatriz Carolina de Araujo and Ferreira, Caio da Silva and Silva, Willian Moreira Leão E and Cardiogenetics Research Group Of Sergipe and Melo, Enaldo Vieira de and Tavares, Irlaneide da Silva and Sousa, Antônio Carlos Sobral and Oliveira, Joselina Luzia Menezes},
  title = {Genetic, Clinical, and Sociodemographic Profile of Individuals with Diagnosis or Family History of Hypertrophic Cardiomyopathy: Insights from a Prospective Cohort},
  journal = {Genes},
  year = {2025},
  doi = {10.3390/genes16091100}
}
Kostenlos starten →